Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 489

1.

Pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark.

Harboe ZB, Valentiner-Branth P, Ingels H, Rasmussen JN, Andersen PH, Bjerre CC, Goldblatt D, Ashton L, Haston M, Konradsen HB, Lambertsen L; Danish Pneumococcal Surveillance Collaborating Group.

PLoS One. 2013;8(1):e51460. doi: 10.1371/journal.pone.0051460. Epub 2013 Jan 24.

2.

Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.

Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF.

Vaccine. 2013 Dec 16;31(52):6232-8. doi: 10.1016/j.vaccine.2013.10.032. Epub 2013 Oct 29.

PMID:
24176490
4.
5.

Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).

American Academy of Pediatrics Committee on Infectious Diseases.

Pediatrics. 2010 Jul;126(1):186-90. doi: 10.1542/peds.2010-1280. Epub 2010 May 24.

PMID:
20498180
6.

Incidence of pediatric invasive pneumococcal disease in the Island of Majorca (2008-2010), an area with non-universal vaccination, and estimations of serotype & children population coverage by available conjugate vaccines.

Picazo J, Dueñas J, Ramirez A, Perez AR, Padilla E, Herrero S, Gallegos C, Culebras E, Balseiro C, Mendez C.

BMC Infect Dis. 2013 Oct 29;13:503. doi: 10.1186/1471-2334-13-503.

7.
8.
9.

Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme.

Ingels H, Rasmussen J, Andersen PH, Harboe ZB, Glismann S, Konradsen H, Hoffmann S, Valentiner-Branth P, Lambertsen L; Danish Pneumococcal Surveillance Collaboration Group 2009-2010.

Vaccine. 2012 Jun 6;30(26):3944-50. doi: 10.1016/j.vaccine.2012.03.060. Epub 2012 Apr 11.

PMID:
22504662
10.

Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020.

Link-Gelles R, Taylor T, Moore MR; Active Bacterial Core Surveillance Team.

Vaccine. 2013 May 24;31(22):2572-7. doi: 10.1016/j.vaccine.2013.03.049. Epub 2013 Apr 11.

PMID:
23583813
11.

Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2010 Mar 12;59(9):253-7.

12.

Expansion of serotype coverage in the universal pediatric vaccination calendar: short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain.

Picazo J, Ruiz-Contreras J, Casado-Flores J, Negreira S, García-de-Miguel MJ, Hernández-Sampelayo T, Otheo E, Méndez C; HERACLES Study Group.

Clin Vaccine Immunol. 2013 Oct;20(10):1524-30. doi: 10.1128/CVI.00239-13. Epub 2013 Aug 7.

13.

Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine.

Miller E, Andrews NJ, Waight PA, Slack MP, George RC.

Vaccine. 2011 Nov 15;29(49):9127-31. doi: 10.1016/j.vaccine.2011.09.112. Epub 2011 Oct 5.

PMID:
21983361
14.

Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine.

Black S, France EK, Isaacman D, Bracken L, Lewis E, Hansen J, Fireman B, Austrian R, Graepel J, Gray S, Klein NP.

Pediatr Infect Dis J. 2007 Sep;26(9):771-7.

PMID:
17721369
15.

Have changing pneumococcal vaccination programmes impacted disease in Ontario?

Lim GH, Wormsbecker AE, McGeer A, Pillai DR, Gubbay JB, Rudnick W, Low DE, Green K, Crowcroft NS, Deeks SL.

Vaccine. 2013 May 31;31(24):2680-5. doi: 10.1016/j.vaccine.2013.04.007. Epub 2013 Apr 16.

PMID:
23597716
16.

Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.

Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, Lévy-Bruhl D; Microbiologists of Epibac; ORP Networks.

Vaccine. 2015 Jan 3;33(2):359-66. doi: 10.1016/j.vaccine.2014.11.011. Epub 2014 Nov 20.

PMID:
25448105
17.
18.

Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.

Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR.

Clin Ther. 2013 Feb;35(2):119-34. doi: 10.1016/j.clinthera.2012.12.006. Epub 2013 Jan 10.

PMID:
23312274
19.

Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.

Farnham AC, Zimmerman CM, Papadouka V, Konty KJ, Zucker JR, Nattanmai GV, Jose S, Rosen JB.

JAMA Pediatr. 2015 Jul;169(7):646-52. doi: 10.1001/jamapediatrics.2015.0612.

PMID:
25938798
20.

Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.

Ben-Shimol S, Greenberg D, Givon-Lavi N, Schlesinger Y, Somekh E, Aviner S, Miron D, Dagan R.

Vaccine. 2014 Jun 5;32(27):3452-9. doi: 10.1016/j.vaccine.2014.03.065. Epub 2014 Mar 30.

PMID:
24690148
Items per page

Supplemental Content

Write to the Help Desk